timothy sykes logo
MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook Thumbnail
G Google News

MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook

JACK KELLOGG•UPDATED AUG. 2, 2026, 10:07 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Myriad Genetics Inc. stocks have been trading down by -45.72 percent amid heightened concern over competitive genetic testing advancements.

Market Insights For Active Traders

  • FY26 revenue outlook was cut to $770M-$790M from $860M-$880M, well below prior targets and Street expectations.
  • Management still expects a strong 66%-67% adjusted gross margin despite weaker Q2 performance.
  • TD Cowen lowered its price target on MYGN from $6 to $4 while keeping a Hold stance.
  • The analyst cited soft Q2 results, greater payer friction, and weaker prenatal trends behind the more cautious 2026 view.

Candlestick Chart

Weekly Update Jul 27 – Jul 31, 2026: On Sunday, August 02, 2026 Myriad Genetics Inc. stock [NASDAQ: MYGN] is trending down by -45.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Myriad Genetics sits in a structurally attractive niche in molecular diagnostics, but the fundamentals are clearly distressed. Revenue of ~$825M growing ~4–5% annually with a 68.8% gross margin is offset by deeply negative profitability (EBIT margin -12%, net margin ~-14%) and severely negative ROIC and ROE. Cash burn persists (Q2 FCF -$11.5M; operating cash flow -$8.3M) despite $116M cash and manageable leverage (total debt/equity 0.69, current ratio 2.2). At ~0.33x sales and 0.8x book, the market is valuing this as a turnaround with high execution risk.

Technically, the stock is in a sharp, high-volume breakdown. The weekly tape shows a collapse from $5.71 to sub-$3 in days, with successive lower highs and lows confirming a dominant downtrend. Intraday 5‑minute candles (not shown numerically but implied by the move) suggest heavy supply on every bounce and little evidence of accumulation. The key actionable level is $3.30–3.40: this former pivot failed, and any rebound into that zone is a low‑risk short entry with stops just above $3.50 until volume stabilizes.

Fundamentally, guidance cuts (FY26 revenue now $770–790M vs prior $860–880M) and increased payer friction put Myriad well behind Healthcare and Diagnostics & Screening peers that are growing faster with positive margins. Sell‑side downgrades (TD Cowen PT to $4) confirm deteriorating sentiment. Near term, resistance sits at $3.30–3.50, with support only around $2.50. Risk‑reward skews negative; the stock is a sell/avoid until clear, sustained profitability progress emerges.

More Breaking News

Quick Financial Overview

Myriad Genetics Inc. is signaling slower growth just as the stock breaks down on the chart. The company now targets FY26 revenue of $770M-$790M, about 10% below its prior $860M-$880M range and under the roughly $863.6M consensus. For traders, that is a clear negative revision and usually forces a reset in how the market values the name. The one positive is that MYGN still expects a healthy 66%-67% adjusted gross margin, which shows the core test business can stay high margin even as top-line growth cools.

On the latest weekly data, MYGN traded around $5.45 earlier in the period, slipped to $5.32, briefly bounced to close at $5.71, and then collapsed toward the low-$3 area. The drop from the $5 handle down to roughly $3.35 and then $2.91 shows heavy repricing after the guidance cut and weak Q2 narrative. Intraday, the 5‑minute candle with a $3.26 high and $2.81 low closing near $2.86 underscores intense volatility and aggressive selling pressure intraday.

Under the hood, Myriad Genetics Inc. is still a high‑gross‑margin but loss‑making business. Trailing revenue is about $824.5M with a gross margin near 68.8%, yet EBIT and net margins are deep in the red, around -12% and -14%. The latest quarter (period ending 2026/06/30) showed $190.7M in revenue but a net loss of $43.2M and operating cash flow of -$8.3M, with free cash flow at about -$11.5M. The balance sheet has roughly $115.2M in cash, total assets of $638.9M, and total liabilities of $335M, supported by a current ratio of 2.2 and debt‑to‑equity near 0.69.

Conclusion

Myriad Genetics Inc. now sits in a classic downgrade phase where fundamentals, guidance, and the chart all align to the downside. A guidance cut from $860M-$880M down to $770M-$790M for FY26 tells traders that growth expectations were too optimistic, and the TD Cowen price target trim to $4 reinforces that message. The violent slide from the mid‑$5s to below $3 in a matter of days shows how quickly sentiment can reset when a story shifts from growth to repair.

At the same time, MYGN still carries some support from its financial structure. Gross margin near 68.8% and a current ratio above 2 suggest the core business has pricing power and near‑term liquidity, even if profitability remains weak. For short‑term traders, the key questions now are whether $3 can stabilize as a base or whether continued concern over payer friction and soft prenatal trends drives another leg down.

In this environment, MYGN is more of a tactical trading vehicle than a steady compounder. Sharp moves around earnings, guidance updates, and analyst calls are likely to continue. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. As I tell my students when a name looks like Myriad Genetics Inc. does today: “You do not get paid for being early, you get paid for being precise — wait for the levels, wait for the volume, and let the chart confirm the shift before you commit real size.”

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”